{"id":4371,"date":"2026-11-16T09:00:00","date_gmt":"2026-11-16T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4371"},"modified":"2026-11-17T20:44:42","modified_gmt":"2026-11-18T00:44:42","slug":"lilly-licenses-stipple-epitope-discovery-programs","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4371","title":{"rendered":"Lilly Licenses Stipple Epitope Discovery Programs"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Stipple_Lilly_Deal_and_Financing-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4372\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Stipple_Lilly_Deal_and_Financing-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Stipple_Lilly_Deal_and_Financing-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Stipple_Lilly_Deal_and_Financing-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Stipple_Lilly_Deal_and_Financing-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_Stipple_Lilly_Deal_and_Financing.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Stipple Bio; Eli Lilly<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Research and exclusive-license agreement (previously missed 16 Nov release)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Epitope-guided targeted oncology (multi-modality)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Pointillist platform; STP-100 ADC separate<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Undisclosed tumor-specific epitopes<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Oncology<\/p>\n<h4>Summary<\/h4>\n<p>Stipple Bio disclosed a multi-target, multi-modality oncology research and license agreement with Lilly on November 16. Lilly receives exclusive worldwide product rights; Stipple receives an undisclosed upfront payment and equity investment and can earn up to $5.9 billion in contingent research, development and commercial milestones plus royalties.<\/p>\n<p>This is a previously missed prior-day release identified in the 14-day source-gap review; it was absent from the November 16 delivered set. The $5.9 billion is maximum contingent milestones, not cash paid or deal value realized. Stipple\u2019s internal STP-100 ADC remains preclinical, with Phase 1 planned for early 2027.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> epitope-level recognition could discriminate malignant from healthy cells even when the target protein is shared, potentially widening the ADC or other targeted-therapy window.<\/p>\n<p><strong>Interpretation B:<\/strong> tumor-specific binding observed in discovery samples may not survive patient heterogeneity, antigen density, processing or tissue cross-reactivity. No targets, binding datasets, payloads, upfront amount or clinical evidence are disclosed. Lilly may be purchasing option breadth, not validating a drug. Translational tests include normal-tissue panels, tumor-cell internalization, linker-payload behavior, PK, bystander effects and manufacturability.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Stipple\u2019s Pointillist platform seeks tumor-specific surface epitopes. Its separately developed STP-100 is a planned antibody-drug conjugate for solid tumors, including pancreatic cancer; licensed Lilly products have undisclosed mechanisms beyond epitope-guided targeting.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Stipple primary release verifies agreement structure.<\/li>\n<li>Missing: number of targets, exact epitope data, candidate selection criteria, upfront and equity amounts.<\/li>\n<li>Upgrade: independent tissue cross-reactivity and human proof of selectivity.<\/li>\n<li>Downgrade: poor differential binding or on-target healthy-tissue toxicity.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The deal supports strategic interest in epitope-level oncology targeting; it does not validate clinical therapeutic index.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: neutral. Confidence in Facts: High. Confidence in Interpretation: Low to Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stipple Bio disclosed a multi-target, multi-modality oncology research and license agreement with Lilly on November 16. Lilly receives exclusive worldwide product rights; Stipple receives an undisclosed upfront payment and equity investment and can earn&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4372,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[92,1524,1523],"class_list":["post-4371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-eli-lilly","tag-epitope-discovery","tag-stipple-bio"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4371"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4371\/revisions"}],"predecessor-version":[{"id":4387,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4371\/revisions\/4387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4372"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}